Ca2+/Calmodulin-dependent Protein Kinase IV Stimulates Nuclear Factor-kappa B Transactivation via Phosphorylation of the p65 Subunit*

Moon Kyoo JangDagger, Young Hwa GooDagger, Young Chang Sohn, Yun Sung Kim, Soo-Kyung Lee§, Heonjoong Kang, JaeHun Cheong, and Jae Woon Lee||

From the Center for Ligand and Transcription, Chonnam National University, Kwangju 500-757 and the  School of Earth and Environmental Sciences, Seoul National University, Seoul 151-742, Korea

Received for publication, November 9, 2000, and in revised form, February 23, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Calmodulin-dependent protein kinase IV (CaMKIV) is a key mediator of Ca2+-induced gene expression. In this study, CaMKIV was found to directly associate with and phosphorylate the nuclear factor-kappa B (NFkappa B) component p65 both in vitro and in vivo. The phosphorylation of p65 by CaMKIV resulted in recruitment of transcription coactivator cAMP-response element-binding protein-binding protein and concomitant release of corepressor silencing mediator for retinoid and thyroid hormone receptors, as demonstrated by the glutathione S-transferase pull down and mammalian two hybrid assays. In addition, cotransfection of CaMKIV resulted in cytosolic translocation of the silencing mediator for retinoid and thyroid hormone receptors. Consistent with these results, cotransfected CaMKIV dramatically stimulated the NFkappa B transactivation in mammalian cells. From these results, NFkappa B is suggested to be a novel downstream effector molecule of CaMKIV.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Calmodulin (CaM)1 is the most ubiquitous and abundant Ca2+-binding protein in cells that is an essential protein that serves as a receptor to sense changes in calcium concentrations and, in this fashion, mediates the second messenger role of this ion (reviewed in Ref. 1). Calcium binds to CaM by means of a structural motif called an EF-hand, and a pair of these structures is located in both globular ends of the protein. CaM binds to and activates target enzymes. These Ca2+/CaM-dependent protein kinases include CaM-kinase kinase, CaMKI and CaMKIV, which are phosphorylated and activated by CaM-kinase kinase, and CaMKII. In particular, CaMKIV is a monomeric multifunctional enzyme that is expressed only in subanatomical portions of the brain, T lymphocytes, and postmeiotic male germ cells. CaMKIV is present in the nucleus of the cells in which it is expressed and has been implicated in regulation of transcription of a number of genes including those encoding interleukin 2, members of the immediate early gene family such as c-fos, tumor necrosis factor family members such as CD40L, FasL, and tumor necrosis factor, the neurotrophin, BDNF, an Epstein-Barr virus gene involved in the switch to the lytic cycle called BZLF1, and orphan members of the steroid receptor superfamily such as ROR and COUP-TF (1). However, the only direct substrates for CaMKIV involved in transcription that have been defined to date are CREB and CREM (2, 3) although the transcription coactivator CREB-binding protein (CBP) has also been indirectly implicated as a possible substrate (4).

Nuclear factor-kappa B (NFkappa B), composed of homo- and heterodimeric complexes of members of the Rel (NFkappa B) family of polypeptides, is important for the inducible expression of a wide variety of cellular and viral genes (reviewed in Ref. 5). In vertebrates, this family comprises p50, p65 (RelA), c-rel, p52, and RelB. These proteins share a 300-amino acid region, known as the Rel homology domain, which binds to DNA and mediates homo- and heterodimerization. This domain is also the target of the Ikappa B proteins, which include Ikappa Balpha , Ikappa Bbeta , Ikappa Bgamma , Bcl-3, p105, and p100. In the majority of cells, NFkappa B exists in an inactive form in the cytoplasm, bound to the inhibitory Ikappa B proteins (5). In response to various inducers, a multisubunit protein kinase, the Ikappa B kinase, is rapidly activated and phosphorylates two critical serine residues in the N-terminal regulatory domain of the Ikappa Bs. Phosphorylated Ikappa Bs are recognized by a specific E3 ubiquitin ligase complex and undergo polyubiquitination, which targets them for rapid degradation by the 26 S proteasome. NFkappa B dimers, which are spared from degradation, translocate to the nucleus to activate gene transcription (5).

Transcriptional coactivators either bridge transcription factors and the components of the basal transcriptional apparatus and/or remodel the chromatin structures (reviewed in Ref. 6). In particular, CBP and its functional homologue p300, as well as steroid receptor coactivator-1 and its family members, were shown to be essential for the activation of transcription by a large number of regulated transcription factors, including NFkappa B (7-9). Interestingly, steroid receptor coactivator-1 and its homologue ACTR, along with CBP and p300, were recently shown to contain histone acetyltransferase activities and associate with yet another histone acetyltransferase protein P/CAF (6). In contrast, nuclear receptor corepressor (N-CoR) and its homologue-silencing mediator for retinoid and thyroid hormone receptors (SMRT) harbor transferable repression domains that can associate with various histone deacetylases (HDAC). In humans, three highly homologous class I (HDAC1, HDAC2, and HDAC3) and four class II (HDAC4, HDAC5, HDAC6, and HDAC7) HDAC enzymes have been identified to date. The class I deacetylases HDAC1 and HDAC2 are components of multisubunit complexes mSin3A and the NuRD complex (10, 11). It is interesting to note that N-CoR/SMRT serves as an adapter molecule between the core mSin3 complex and sequence-specific transcriptional repressors without stably associating with the mSin3 complex. More recently, however, SMRT/N-CoR was found to be a direct component of a newly isolated HDAC3 complex (12, 13). N-CoR and SMRT have also been reported to partner with HDAC4, HDAC5, and HDAC7 (14, 15). These results are consistent with the notion that acetylation of histones destabilizes nucleosomes and relieves transcriptional repression by allowing transcription factors to access to recognition elements, whereas deacetylation of the histones stabilizes the repressed state (6). Interestingly, N-CoR/SMRT is also known to mediate transcriptional repression from a wide variety of other non-receptor-mediated pathways (16-21). These include AP-1, NFkappa B, SRF, MyoD, the bHLH-LZ proteins Mad and Mxi that mediate repression of Myc activities and tumor suppression, E2F-repressive retinoblastoma protein, and the oncoproteins PLZF-RAR and LAZ3/BCL6, which are involved in acute promyelocytic leukemia and non-Hodgkin's lymphomas, respectively.

In this work, we found that CaMKIV specifically interacted with and phosphorylated the NFkappa B component p65, and the CaMKIV-mediated phosphorylation of p65 resulted in enhanced recruitment of CBP with concomitant dissociation of SMRT. In addition, cotransfection of CaMKIV resulted in cytosolic translocation of SMRT. Accordingly, CaMKIV dramatically stimulated the NFkappa B transactivation. From these results, we concluded that NFkappa B is a novel downstream effector molecule of CaMKIV.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Plasmids, Chemicals, Cells, and Antibodies-- The polymerase chain reaction-amplified fragments for the full-length CaMKIV, CaMKIVc (the CaMKIV residues 1-313), and CREB were subcloned into EcoRI and XhoI (or SalI) restriction sites of the LexA fusion vector pEG202PL, the B42 fusion vector pJG4-5, the mammalian two hybrid vectors pCMX/Gal4 and pCMX/VP16, and the mammalian expression/in vitro translation vector pcDNA3. The polymerase chain reaction-amplified fragments for CaMKIV, CaMKIVc, human p65, and p65C (the p65 residues 431-551) were inserted into EcoRI and XhoI restriction sites of the glutathione S-transferase (GST) fusion vector pGEX4T-1. Expression vectors for various CaMKs and their C-terminal deleted forms with constitutive activities were obtained from Dr. Tony Means at Duke University. The mammalian two hybrid vectors pCMX/VP16-SMRT-D, pCMX/VP16-CBP-A, pCMX/Gal4-p65, and pCMX/VP16-p65, the mammalian expression vectors for p65, CBP, CBP-A, SMRT-D, GFP/SMRT, and a constitutively active form of MEKK-1, and the yeast expression vectors encoding B42 fusions to p50 and p65C were as described (9, 16, 22-24). CV-1 and HeLa cells were obtained from ATCC (Manassas, VA), and polyclonal antibodies against p65 and CaMKIV were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Calcium signaling activator ionomycin and CaMK inhibitor KN-93 were purchased from Calbiochem.

Cell Culture, Transfection, and Microscopy-- HeLa and CV-1 cells (5 × 104 cells/well) were grown in 24-well plates with Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum for 24 h and transiently transfected using SuperFect (Qiagen, Valencia, CA) according to the manufacturer's instructions. The cells were harvested 48 h later, the luciferase assays were done as described (25), and the results were normalized to the LacZ expression. For treatment with ionomycin and KN-93, the cells, 24 h post-transfection, were replaced with fresh medium containing ionomycin or KN-93. The cells were lysed 24 h later. For the localization studies of SMRT, ~105 CV-1 cells were seeded in a chambered coverslip cell culture system (Nalge-Nunc, Rochester, NY) and were transfected with the pCMV-GFP-SMRT vector (24), together with an appropriate expression vector for the activated form of MEKK-1 (24) or various CaMKs, as indicated (or an equivalent empty vector as a control) using the SuperFect procedure. One day after transfection, the subcellular location of the GFP-SMRT fusion polypeptide was visualized using a Zeiss AxiosKop 2 microscope.

The Yeast beta -Galactosidase Assay-- The cotransformation and beta -galactosidase assay in yeast were done as described (25). For each experiment, at least three independently derived colonies expressing chimeric proteins were tested.

GST Pull Down Assays-- Equal amounts of GST alone or GST fusion proteins, expressed in Escherichia coli and purified, were bound to glutathione-Sepharose 4B beads and incubated in the reaction buffer (100 mM NaCl, 25 mM Hepes (pH 7.9), 20% glycerol, 0.2 mM EDTA, 1 mM dithiothreitol, and 1.5% bovine serum albumin) with labeled proteins expressed by in vitro translation by using the TNT-coupled transcription-translation system, with conditions as described by the manufacturer (Promega, Madison, WI). Specifically bound proteins were eluted from beads with 40 mM reduced glutathione in 50 mM Tris (pH 8.0) and analyzed by SDS-PAGE and autoradiography as described (25).

Phosphorylation in Vivoand in Vitro-- For in vivo phosphorylation, HeLa cells were cultured in 100-mm dish at density of 1 × 105 cells/ml for 24 h, transfected with 5 µg of the indicated expression vectors using SuperFect, grown for 24 h, starved in serum-free Dulbecco's modified Eagle's medium for 30 min, and treated with 100 µCi of [32P]orthophosphate. 3 h later, the cells were washed three times with phosphate-buffered saline, lysed in 0.2 ml of lysis buffer (50 mM Tris (pH 7.5), 300 mM NaCl, 1 mM EDTA, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, 20 mM NaF, 5 mM sodium orthovanadate, and 1× phosphatase inhibitor), and centrifuged. The supernatant was immunoprecipitated with 10 µl of p65-specific antibody for 2 h and incubated with protein A-agarose for 16 h. The immunoprecipitates were washed three times with lysis buffer and analyzed by SDS-PAGE and autoradiography. Purified GST alone and GST fusion protein to p65C were subjected to phosphorylation with either cold ATP or [gamma -32P]ATP for labeling. CaMKIV was expressed by in vitro translation by using the TNT-coupled transcription-translation system and purified by immunoprecipitation with CaMKIV-specific antibody. Alternatively, HeLa cells cotransfected with indicated expression vectors were lysed, immunoprecipitated with p65 antibody, washed three times with phosphate-buffered saline, and utilized as a source for putative p65-associated kinase(s) in vivo. Kinase reactions were carried out for 30 min at 30 °C with 25 mM Hepes (pH 7.6), 10 mM MgCl2, 5 µM [gamma -32P]ATP, 1 mM dithiothreitol, and 5% glycerol. To activate the full-length CaMKIV, 1 mM CaCl2 and 10 µg/ml of CaM were added.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

The Direct Interaction of CaMKIV with NFkappa B-- It is interesting to note that there are significant overlaps in function between NFkappa B and CaMKIV, such as their involvement in anti-apoptosis and pro-proliferation (1, 5). Furthermore, CaMKIV is known to reside in the nucleus in vivo and directly phosphorylate the transcription factors CREB and CREM (2, 3). Thus, we tested whether CaMKIV is also functionally linked to NFkappa B. As shown in Fig. 1A, the constitutively active mutant form of CaMKIV consisting of the CaMKIV residues 1-313 (i.e. CaMKIVc) was found to interact with the NFkappa B components p50 and p65 in yeast. In the case of p65, p65C consisting of the C-terminal transactivation domain of p65 (i.e. the p65 residues 431-551) was utilized, because the full-length p65 was not readily expressed. As expected, the positive control CREB was also found to directly interact with CaMKIVc in yeast. Similar results were also obtained with the full-length CaMKIV (data not shown). Consistent with these results, coexpression of a fusion protein consisting of the transactivation domain VP16 and CaMKIVc stimulated the Gal4/p65-directed transactivation in HeLa cells, suggesting that p65 directly interacts with CaMKIV in vivo (Fig. 1B). In this experiment, it is notable that 20 µM of the CaMK inhibitor KN-93 was used, because VP16/CaMKIVc alone was an effective stimulator of the Gal4/p65 transactivation in the absence of KN-93 (data not shown). Coexpression of VP16/p65 also stimulated the Gal4/CaMKIV-mediated level of transactivation directed by the Gal4-Luc reporter construct (data not shown). Finally, labeled p65 protein expressed by using the TNT-coupled in vitro transcription-translation system specifically interacted with GST fusions to the full-length CaMKIV and CaMKIVc but not with GST alone (Fig. 1C). Interestingly, the p50-CaMKIV interaction was much weaker in the mammalian two hybrid tests and not readily observed in the GST pull down assays (data not shown), suggesting that an intermediary protein(s) may mediate the observed in vivo interactions between CaMKIV and p50 in yeast. Nevertheless, these results strongly suggest that specific interactions may occur between CaMKIV and NFkappa B in vivo.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 1.   Direct interactions of CaMKIV and NFkappa B. A, the indicated B42 and LexA plasmids were transformed into a yeast strain containing an appropriate LacZ reporter gene as described (25). Open and closed boxes indicate the presence of LexA alone and LexA fusion to CaMKIVc, respectively. The p65 residues 431-551 were included in p65C. The data are representative of at least two similar experiments, and the error bars are as indicated. B, HeLa cells were transfected with LacZ expression vector and VP16 fusion to CaMKIVc, along with an expression vector for Gal4/p65 and a reporter gene, Gal4-Luc, as indicated. Normalized luciferase expressions from triplicate samples were calculated relative to the LacZ expressions, and the results were expressed as -fold activation (n-fold) over the value obtained with Gal4-Luc alone. To suppress the intrinsic transcriptional stimulatory effect of VP16/CaMKIVc on Gal4/p65, 20 µM of the CaMK inhibitor KN-93 was added. Similar results were also obtained with CV-1 cells. The data are representative of three similar experiments, and the error bars are as indicated. C, the full-length p65 was labeled with [35S]methionine by in vitro translation and incubated with glutathione beads containing GST alone, GST/CaMKIV, and GST/CaMKIVc, as indicated. Beads were washed, and specifically bound material was eluted with reduced glutathione and resolved by SDS-PAGE. Approximately 20% of the total reaction mixture was loaded as input.

Phosphorylation of p65 by CaMKIV-- The direct physical interactions between the NFkappa B component p65 and CaMKIV in vitro (Fig. 1C) suggested that p65 may serve as a direct substrate for the kinase activity of CaMKIV. Thus, we tested whether p65 can be phosphorylated by CaMKIV in vivo. HeLa cells transfected with either the parental vector pcDNA3 or pcDNA3-CaMKIVc were subjected to in vivo phosphorylation by incubating the cells in the presence of 100 µCi of [32P]orthophosphate. The cells were lysed and immunoprecipitated by either preserum or antibody against p65. As shown in Fig. 2A, fractionation of the lysed extracts in SDS-PAGE and autoradiography showed that the p65 immunoprecipitates but not the preserum-directed immunoprecipitates contained a labeled p65 band. The labeling intensity of the identical band was significantly increased in CaMKIVc-transfected cell extracts. The total amounts of p65 were identical between these samples (data not shown), excluding the possibility that CaMKIVc increased the expression level of p65. These results imply that p65 is either a direct or indirect phosphorylation target of CaMKIV in vivo. To distinguish between these possibilities, purified GST alone or GST fusion proteins to p50, p65, and p65C were subjected to [gamma -32P]ATP-phosphorylation with CaMKIV, either in the absence or presence of CaMK-activating CaM. For these reactions, we utilized in vitro-translated CaMKIV, which was purified further by immunoprecipitating with specific antibody against CaMKIV to exclude other kinase activities included in the in vitro translation reactions. As expected, GST/p65C but not GST alone was specifically labeled with 32P only in the presence of CaM (Fig. 2B). Interestingly, phosphorylation of p50 was not observed in these experiments, consistent with the lack of its direct interactions with CaMKIV in vitro, whereas the overexposure of the film revealed some weak labeling with the full-length p65 (data not shown). These results suggest that efficient phosphorylation of the full-length p65 in vivo may require other additional proteins or signaling events that are not present in the in vitro reactions. Nevertheless, these results clearly demonstrate that the C-terminal transactivation domain of p65 is a direct phosphorylation substrate of CaMKIV. Finally, we tested whether p65 is associated with CaMK in vivo. To this end, p65 antibody-directed immunoprecipitates from lysates of HeLa cells transfected with either p65 or p65 plus CaMKIV were utilized as a source for kinase to phosphorylate GST alone, GST/p65, and GST/p65C as substrates. In these experiments, GST/p65C but not GST alone was labeled with [gamma -32P]ATP only in the presence of CaMK-activating CaM when using cells transfected with p65 alone (Fig. 2C, compare lanes 1 and 2). Similarly, HeLa cells cotransfected with both p65 and CaMKIV exhibited a detectable, basal level of phosphorylation with GST/p65C (Fig. 2C, lane 3), which was further strengthened with addition of CaM (Fig. 2C, lane 4). In particular, phosphorylation of GST fusion to the full-length p65 was readily detectable under this condition (Fig. 2C, lanes 5 and 6). Thus, the putative proteins or signaling events required for efficient phosphorylation of the full-length p65 in vivo may exist in this p65 antibody-directed immunoprecipitate. Notably, CaMKIV is known to be expressed only in certain cell types whereas CaMKI and CaMKII are ubiquitous in expression. Thus, the CaMK found to be associated with p65 in vivo in the absence of cotransfected CaMKIV (Fig. 2C, lane 2) is likely to be either CaMKI or CaMKII. Overall, these results strongly demonstrate that the endogenous CaMK in HeLa cells or cotransfected CaMKIV specifically associates with and phosphorylates p65 in vivo.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 2.   Phosphorylation of p65 by CaMKIV. A, HeLa cells were transfected with either vector alone (i.e. pcDNA3) or pcDNA3-CaMKIVc and subjected to in vivo phosphorylation by incubating the cells in the presence of 100 µCi of [32P]orthophosphate. The lysed cells were immunoprecipitated by either preserum or antibody against p65 and analyzed by SDS-PAGE and autoradiography. The total amounts of p65 were identical between these samples as judged by Western analysis (data not shown). IP and T indicate immunoprecipitation and cotransfection, respectively. B, GST alone and GST fusion protein to p65C were expressed in E. coli, purified, and subjected to [gamma -32P]ATP phosphorylation with in vitro-translated and purified CaMKIV, either in the absence or presence of CaM. The labeled bands were analyzed by SDS-PAGE and autoradiography. C, lysates of HeLa cells cotransfected with p65 alone or p65 plus CaMKIV-expression vectors were immunoprecipitated with antibody against p65, washed extensively, and utilized as a putative kinase to phosphorylate purified GST alone, GST/p65, or GST/p65C as substrates. T indicates cotransfection.

Recruitment of CBP and Release of SMRT by CaMKIV-phosphorylated p65-- The fact that the CaMKIV-directed phosphorylation site was mapped to the C-terminal transactivation domain of p65, which was previously shown to be the interaction interfaces of both transcription coactivator CBP and corepressor SMRT/N-CoR (7, 8, 16), led us to test whether CaMKIV-directed phosphorylation of p65 affects its interactions with these transcription cofactor molecules. Indeed, the mammalian two hybrid-based assays demonstrated that coexpressed CaMKIVc strengthened the interactions of Gal4/p65 and VP16/CBP-A (Fig. 3A). In contrast, the interactions between Gal4/p65 and VP16/SMRT-D were significantly impaired by coexpressed CaMKIVc. CBP-A (i.e. the CBP residues 1-446) and SMRT-D (i.e. the SMRT residues 1060-1495) are the previously defined p65 interaction interfaces (7, 8, 16). Consistently, these results were also recapitulated in the in vitro GST pull down assays. Radiolabeled CBP-A interacted with p65C, which was reacted with CaM-activated CaMKIV but not CaMKIV alone and washed extensively prior to being added to the GST pull down assays (Fig. 3B). Consistent with the mammalian two hybrid tests, interactions of unphosphorylated GST/p65C and radiolabeled SMRT-D were lost when p65C was phosphorylated by CaM-activated CaMKIV (Fig. 3B). As expected, GST alone did not interact with radiolabeled CBP-A or SMRT-D under any condition. Overall, these results clearly demonstrate that CaMKIV-directed phosphorylation of p65 results in efficient recruitment of transcription coactivator CBP while repulsing corepressor SMRT.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 3.   Recruitment of CBP and release of SMRT by CaMKIV-phosphorylated p65. A, CV-1 cells were transfected with LacZ expression vector and VP16 fusion to CBP-A and SMRT-D, along with expression vectors for Gal4/p65 and CaMKIVc and a reporter gene, Gal4-Luc, as indicated. Normalized luciferase expressions from triplicate samples were calculated relative to the LacZ expressions, and the results were expressed as -fold activation (n-fold) over the value obtained with Gal4-Luc alone. The data are representative of three similar experiments, and the error bars are as indicated. CBP-A (i.e. the CBP residues 1-446) and SMRT-D (i.e. the SMRT residues 1060-1495) are the previously defined p65 interaction interfaces (7, 8, 16). Similar results were also obtained with HeLa cells. B, CBP-A and SMRT-D were labeled with [35S]methionine by in vitro translation and incubated with glutathione beads containing GST alone and GST/p65C. Prior to the GST pull down reactions, both GST proteins were subjected to CaMKIV-mediated kinase reactions, in either the absence or presence of CaM, and washed extensively. CaMKIV was expressed by in vitro translation by using the TNT-coupled transcription-translation system and purified by immunoprecipitation with CaMKIV-specific antibody. Beads were washed, and specifically bound material was eluted with reduced glutathione and resolved by SDS-PAGE. Approximately 20% of the total reaction mixture was loaded as input.

CaMKIV-mediated Translocation of SMRT-- Recently, CaMK signaling was shown to promote myogenesis by disrupting MEF2·HDAC complexes and stimulating HDAC nuclear export (26, 27). Similarly, phosphorylation of SMRT by MEKK-1 was shown to inhibit the ability of SMRT to physically tether to its transcription factor partners and led to a redistribution of the SMRT protein from a nuclear compartment to a more perinuclear or cytoplasmic compartment (24). These results led us to explore whether CaMKIV has a similar modulatory role with SMRT. As shown in Fig. 4, cotransfection with CaMKIVc expression vector resulted in more cells that express GFP/SMRT in the cytoplasm. In the absence of CaMKc, ~73% of cells had the previously described, speckled pattern of exclusive nuclear expression with SMRT (6). In contrast, however, ~75% of cotransfected cells exhibited cytoplasmic staining of SMRT in the presence of CaMKIVc. In these cells, nuclear staining was still observed, but the number of speckles was significantly decreased. Similar results were also obtained with CaMKIc, whereas CaMKIIc was without any significant effect. As reported (24), the active form of MEKK-1 also led to the cytoplasmic translocation of SMRT. These results strongly suggest that CaMKI and CaMKIV may stimulate SMRT nuclear export. Currently, we are investigating whether CaMKIV, either directly or indirectly, phosphorylates SMRT. However, close examinations of the SMRT sequences revealed that they lack the known consensus phosphorylation sequences for CaMKIV, (R/K)XX(S/T) (1).


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 4.   CAMKIV-mediated translocation of SMRT. CV-1 cells were transfected with an expression vector encoding GFP fused to SMRT (24), along with expression vectors encoding various kinases, as indicated. Under a fluorescence microscope, cells were counted against the location of GFP/SMRT expression (i.e. cytoplasmic versus nuclear). Each data point represents the average percentage of two independent experiments of at least 200 cells per experiment. C, cytoplasmic; N, nuclear.

Stimulation of the NFkappa B Transactivation by CaMKIV-- The above results suggest that CaMKIV should serve as an activator of the NFkappa B transactivation. This prediction was confirmed in experiments in which Gal4/p65-directed transactivation of the Gal4-Luc reporter construct (9, 16) was significantly enhanced by coexpressed CaMKIVc in a dose-dependent manner in CV-1 cells (Fig. 5A). Similarly, coexpressed CaMKIVc stimulated the NFkappa B transactivation with the kappa B-Luc reporter construct (9, 16) (Fig. 5B). In addition, CBP-dependent stimulation of the p65 transactivation (7, 8) was synergistically enhanced by coexpressed CaMKIVc (Fig. 5B). Similar results were also obtained in HeLa cells (data not shown). The C-terminally deleted, constitutive active form of CaMKI but not CaMKII showed dramatic stimulatory effects on the NFkappa B transactivation (Fig. 5C). Thus, CaMKI is likely to represent the CaMK proposed to be associated with p65 in vivo (Fig. 2C). Treatment of HeLa cells with ionomycin, the CaMK activator, either in the absence or presence of coexpressed CaMKIV, also led to stimulation of the p65-directed transactivation of the kappa B-Luc reporter construct in HeLa cells, whereas the CaMKIVc-stimulated level of the p65 transactivation was impaired by KN-93, the CaMK inhibitor, in a dose-dependent manner (Fig. 5D). As already noted, the ionomycin effect on the p65 transactivation in HeLa cells non-transfected with CaMKIV is probably because of the endogenous CaMKI. Accordingly, the inhibition was relatively minor with 3 µM KN-93, the concentration that is known to specifically inhibit CaMKII, whereas 30 µM KN-93, at which both CaMKI and CaMKIV are inhibited, completely blocked the p65 transactivation (Fig. 5D). From these results, we concluded that CaMKI and CaMKIV are capable of stimulating the NFkappa B transactivation, likely through direct phosphorylation of p65 and other proteins that appears to result in efficient recruitment of transcription coactivator CBP while disrupting the p65-SMRT interactions and stimulating nuclear export of corepressor SMRT.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 5.   Stimulation of the NFkappa B transactivation by CaMKIV. CV-1 or HeLa cells were transfected with LacZ expression vector and various reporter genes and expression vectors, as indicated. CaMKIc (the CaMKI residues 1-295) and CaMKIIc (the CaMKII residues 1-290) are the C-terminal deletion mutant forms with constitutive kinase activities (1), like CaMKIVc (C). ion indicates CaMK activator ionomycin (0.12 µM), and KN denotes CaMK inhibitor KN-93 (3 µM and 30 µM, respectively) (D). 25 ng of each CaMK was cotransfected in C and D. Normalized luciferase expressions from triplicate samples were calculated relative to the LacZ expressions. and the results were expressed as -fold activation (n-fold) over the value obtained with a reporter alone. The data are representative of three similar experiments, and the error bars are as indicated.

Several reports have demonstrated that inhibition of CaMK activity is associated with apoptosis and proliferation. Inhibition of CaMK activity with specific inhibitors induces apoptosis in NIH 3T3 cells (28) and sensitizes etoposide-resistant cells to apoptotic challenge (29). Thymic T cells from transgenic mice expressing a catalytically inactive form of CaMKIV showed defects in survival and proliferation (30). Similarly, CaMK inhibitor KN-62 was shown to reduce DNA synthesis in small cell lung carcinoma (31). It is interesting to note that NFkappa B has also been linked to both anti-apoptosis and pro-proliferative activities (reviewed in Refs. 32 and 33). Thus, NFkappa B may mediate these previously characterized anti-apoptotic and pro-proliferative effects of CaMKIV, although other activities of CaMKIV previously known and/or yet to be characterized may also turn out to operate through NFkappa B. Similar to the work described in this report, p65 was recently shown to be phosphorylated by the Ikappa B-associated PKAc subunit through a cyclic AMP-independent mechanism, which promoted a novel bivalent interaction of p65 with the coactivator CBP/p300 (34, 35). Thus, p65 appears to be directly phosphorylated by at least two distinct kinases. Finally, the C-terminal transactivation domain of p65 is noted to have a numerous number of phosphorylation sites, including consensus CaMK sites ((R/K)XX(S/T)) (1), and an effort to precisely map the regulatory phosphorylation sites of p65 by CaMKIV is currently under progress.2

In conclusion, we have shown that CaMKIV specifically interacts with and phosphorylates the NFkappa B component p65, which results in augmented transcriptional activity of p65 by facilitated dissociation of SMRT with concomitant, enhanced recruitment of CBP. CaMKIV also stimulated the nuclear export of SMRT. Overall, these results suggest that the NFkappa B component p65 may serve as a novel downstream phosphorylation target of CaMKIV and act as one of its effector molecules in vivo.

    ACKNOWLEDGEMENTS

We thank Dr. Tony Means for various CaMK plasmids.

    FOOTNOTES

* This work was exclusively supported by a grant from the National Creative Research Initiatives Program of the Korean Ministry of Science and Technology, Republic of Korea.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Contributed equally.

§ Present address: Salk Inst., San Diego, CA 92185.

|| To whom correspondence should be addressed. Tel.: 82-62-530-0910; Fax: 82-62-530-0772; E-mail: jlee@chonnam.chonnam.ac.kr.

Published, JBC Papers in Press, March 26, 2001, DOI 10.1074/jbc.M010211200

2 M. K. Jang, J. Cheong, and J. W. Lee, unpublished results.

    ABBREVIATIONS

The abbreviations used are: CaM, calmodulin; CaMK, Ca2+/CaM-dependent protein kinase; CREB, cAMP-response element-binding protein; CBP, CREB-binding protein; NFkappa B, nuclear factor-kappa B; N-CoR, nuclear receptor corepressor; SMRT, silencing mediator for retinoid and thyroid hormone receptors; HDAC, histone deacetylases; GST, glutathione S-transferase; PAGE, polyacrylamide gel electrophoresis; GFP, green fluorescent protein; MEKK, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase; Luc, luciferase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

1. Means, A. R. (2000) Mol. Endocrinol. 14, 4-13[Free Full Text]
2. Schulman, H., and Braun, A. (1999) in Calcium as a Cellular Regulator (Carafoli, E. , and Klee, C., eds) , pp. 311-343, Oxford University Press, New York
3. Means, A. R., Ribar, T. J., Kane, C. D., Hook, S. S., and Anderson, K. A. (1997) Recent Prog. Horm. Res. 52, 389-407[Medline] [Order article via Infotrieve]
4. Chawla, S., Hardingham, G. E., Quinn, D. R., and Bading, H. (1998) Science 281, 1505-1509[Abstract/Free Full Text]
5. Karin, M., and Delhase, M. (2000) Semin. Immunol. 12, 85-98[CrossRef][Medline] [Order article via Infotrieve]
6. Westin, S., Rosenfeld, M. G., and Glass, C. K. (2000) Adv. Pharmacol. 47, 89-112[Medline] [Order article via Infotrieve]
7. Gerritsen, M. E., Williams, A. J., Neish, A. S., Moore, S., Shi, Y., and Collins, T. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2927-2932[Abstract/Free Full Text]
8. Perkins, N. D., Felzien, L. K., Betts, J. C., Leung, K., Beach, D. H., and Nabel, G. J. (1997) Science 275, 523-527[Abstract/Free Full Text]
9. Na, S.-Y., Lee, S.-K., Han, S. J., Choi, H. S., Im, S. Y., and Lee, J. W. (1998) J. Biol. Chem. 273, 10831-10834[Abstract/Free Full Text]
10. Heinzel, T., Lavinsky, R. M., Mullen, T. M., Soderstrom, M., Laherty, C. D., Torchia, J., Yang, W. M., Brard, G., Ngo, S. D., Davie, J. R., Seto, E., Eisenman, R. N., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. (1997) Nature 387, 43-48[CrossRef][Medline] [Order article via Infotrieve]
11. Nagy, L., Kao, H. Y., Chakravarti, D., Lin, R. J., Hassig, C. A., Ayer, D. E., Schreiber, S. L., and Evans, R. M. (1997) Cell 89, 373-380[Medline] [Order article via Infotrieve]
12. Wen, Y. D., Perissi, V., Staszewski, L. M., Yang, W. M., Krones, A., Glass, C. K., Rosenfeld, M. G., and Seto, E. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 7202-7207[Abstract/Free Full Text]
13. Guenther, M. G., Lane, W. S., Fischle, W., Verdin, E., Lazar, M. A., and Shiekhattar, R. (2000) Genes Dev. 14, 1048-1057[Abstract/Free Full Text]
14. Kao, H. Y., Downes, M., Ordentlich, P., and Evans, R. M. (2000) Genes Dev. 14, 55-66[Abstract/Free Full Text]
15. Huang, E. Y., Zhang, J., Miska, E. A., Guenther, M. G., Kouzarides, T., and Lazar, M. A. (2000) Genes Dev. 14, 45-54[Abstract/Free Full Text]
16. Lee, S.-K., Kim, J. H., Lee, Y. C., Cheong, J., and Lee, J. W. (2000) J. Biol. Chem. 275, 12470-12474[Abstract/Free Full Text]
17. Bailey, P., Downes, M., Lau, P., Harris, J., Chen, S. L., Hamamori, Y., Sartorelli, V., and Muscat, G. E. (1999) Mol. Endocrinol. 13, 1155-1168[Abstract/Free Full Text]
18. Laherty, C. D., Yang, W. M., Sun, J. M., Davie, J. R., Seto, E., and Eisenman, R. N. (1997) Cell 89, 349-356[Medline] [Order article via Infotrieve]
19. Lai, A., Lee, J. M., Yang, W. M., DeCaprio, J. A., Kaelin, W. G., Jr., Seto, E., and Branton, P. E. (1999) Mol. Cell. Biol. 19, 6632-6641[Abstract/Free Full Text]
20. Lin, R. J., Nagy, L., Inoue, S., Shao, W., Miller, W. H., Jr., and Evans, R. M. (1998) Nature 391, 811-814[CrossRef][Medline] [Order article via Infotrieve]
21. Dhordain, P., Albagli, O., Lin, R. J., Ansieau, S., Quief, S., Leutz, A., Kerckaert, J. P., Evans, R. M., and Leprince, D. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 10762-10767[Abstract/Free Full Text]
22. Lee, S.-K., Anzick, S. L., Choi, J. E., Bubendorf, L., Guan, X. Y., Jung, Y. K., Kallioniemi, O. P., Kononen, J., Trent, J. M., Azorsa, D., Jhun, B. H., Cheong, J., Lee, Y. C., Meltzer, P. S., and Lee, J. W. (1999) J. Biol. Chem. 274, 34283-34293[Abstract/Free Full Text]
23. Lee, S.-K., Na, S.-Y., Jung, S. Y., Choi, J. E., Jhun, B. H., Cheong, J., Meltzer, P. S., Lee, Y. C., and Lee, J. W. (2000) Mol. Endocrinol. 14, 915-925[Abstract/Free Full Text]
24. Hong, S. H., and Privalsky, M. L. (2000) Mol. Cell. Biol. 20, 6612-6625[Abstract/Free Full Text]
25. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1995) Current Protocols in Molecular Biology , Greene Associates, NY
26. McKinsey, T. A., Zhang, C. L., Lu, J., and Olson, E. N. (2000) Nature 408, 106-111[CrossRef][Medline] [Order article via Infotrieve]
27. McKinsey, T. A., Zhang, C. L., and Olson, E. N. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 14400-14405[Abstract/Free Full Text]
28. Tombes, R. M., Grant, S., Westin, E. H., and Krystal, G. (1995) Cell Growth Differ. 6, 1063-1070[Abstract]
29. Kawamura, K., Grabowski, D., Krivacic, K., Hidaka, H., and Ganapathi, R. (1996) Biochem. Pharmacol. 52, 1903-1909[CrossRef][Medline] [Order article via Infotrieve]
30. Anderson, K. A., Ribar, T. J., Illario, M., and Means, A. R. (1997) Mol. Endocrinol. 11, 725-737[Abstract/Free Full Text]
31. Williams, C. L., Phelps, S. H., and Porter, R. A. (1996) Biochem. Pharmacol. 51, 707-715[CrossRef][Medline] [Order article via Infotrieve]
32. Natoli, G., Costanzo, A., Guido, F., Moretti, F., and Levrero, M. (1998) Biochem. Pharmacol. 56, 915-920[CrossRef][Medline] [Order article via Infotrieve]
33. Rayet, B., and Gelinas, C. (1999) Oncogene 18, 6938-6947[CrossRef][Medline] [Order article via Infotrieve]
34. Zhong, H., SuYang, H., Erdjument-Bromage, H., Tempst, P., and Ghosh, S. (1997) Cell 89, 413-424[Medline] [Order article via Infotrieve]
35. Zhong, H., Voll, R. E., and Ghosh, S. (1998) Mol. Cell. 1, 661-671[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.